Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | APAF1 | O14727 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832541 | 1.00 | KMT2A (0.67) | KMT2ARAB9ANPC1CYP2A6MAOA | |
| Hydrochloric Acid SCHEMBL4557636 | 0.98 | KMT2A (0.65) | KMT2ARAB9ANPC1CYP2A6MAOA | |
| Formic Acid SCHEMBL38654533 | 0.92 | KMT2A (0.57) | KMT2ARAB9ANPC1CYP2A6MAOA | |
| SCHEMBL31352634 | 0.91 | KMT2A (0.59) | KMT2ARAB9ANPC1CYP2A6MAOA | |
| Trifluoroacetic Acid SCHEMBL30727536 | 0.87 | KMT2A (0.51) | KMT2ARAB9ANPC1RNASEH1PKM | |
| Diftalone SCHEMBL35351 | 0.81 | KMT2A (1.00) | KMT2ARAB9ANPC1MAOARNASEH1 | |
| Diftalone SCHEMBL29644941 | 0.81 | KMT2A (1.00) | KMT2ARAB9ANPC1MAOARNASEH1 | |
| SCHEMBL28840917 | 0.81 | KMT2A (0.59) | KMT2ARAB9ANPC1RNASEH1PKM | |
| SCHEMBL30736409 | 0.79 | KMT2A (0.61) | KMT2ARAB9ANPC1RNASEH1PKM | |
| SCHEMBL30213314 | 0.78 | CRBN (0.44) | KMT2ARAB9ANPC1MAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | claimed |
| CN-114728950-B | Compounds useful as inhibitors of HELIOS proteins | 百时美施贵宝公司 | 2024-10-18 | — | — | CN | claimed |
| CN-111051298-B | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-121532390-A | Glutarimido isoindoles Compounds of the pinone skeleton | 标新生物医药科技(上海)有限公司 | 2026-02-13 | — | — | CN | disclosed |
| WO-2025162225-A1 | COMPOUND WITH NEW SUBSTITUTED GLUTARIMIDO-ISOINDOLINONE FRAMEWORK, AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2025-08-07 | — | — | WO | disclosed |
| EP-4541795-A1 | AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2025-04-23 | — | — | EP | disclosed |
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | Tiger Biotherapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118834201-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-114728950-B | Compounds useful as inhibitors of HELIOS proteins | 百时美施贵宝公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114656452-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2023278325-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-115068484-A | Treatment of immune-related and inflammatory diseases | 细胞基因公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4021450-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114656452-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114286678-A | Compounds for inhibiting and inducing degradation of EGFR and ALK | 北京泰德制药股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168058-B2 | Glutarimide-containing KRAS-mutant degrader compounds and uses thereof | KRAS, VHL, HRAS | KMT2A 1618/4885RAB9A 129/4885NPC1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.